NCT00558675View on ClinicalTrials.gov

A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2013

Conditions
Hematological MalignancyLeukemiaLymphomaMultiple Myeloma
Interventions
BIOLOGICAL

AlloStim

single intravenous infusion of 1 x 10\^9 AlloStim cells

BIOLOGICAL

AlloStim

Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7

BIOLOGICAL

AlloStim

Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14

BIOLOGICAL

AlloStim

Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21

Trial Locations (1)

91120

Hadassah-Hebrew University Medical Center, Jerusalem

Sponsors
All Listed Sponsors
collaborator

Hadassah Medical Organization

OTHER

lead

Mirror Biologics, Inc.

INDUSTRY

NCT00558675 - A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | Biotech Hunter | Biotech Hunter